Moxifloxacin is a fluoroquinolone antibiotic with broad-spectrum antimicrobial activity. Despite reports of moxifloxacin-related side effects such as interstitial nephritis, recurrent tendinitis, and ...

Findings from OPTIC-2 showed omadacycline was noninferior to moxifloxacin based on early clinical response rates. Omadacycline was found to be noninferior to moxifloxacin in the treatment of ...

A retrospective study compared moxifloxacin and azithromycin in treating severe refractory Mycoplasma pneumoniae pneumonia (SRMPP) in children, finding no significant differences in clinical outcomes ...

Are you taking Moxifloxacin? Are you aware of the dangers of combining Moxifloxacin with certain foods, herbs or alcohol? Drug-food-interactions are seldom discussed but can lead to undesirable ...

Moxifloxacin is a fourth-generation fluoroquinolone antibiotic approved for use in the United States in 1999 (Soto et al., 2002). It is on the World Health Organization’s List of Essential Medicines ...

A new study has confirmed that moxifloxacin, a fluoroquinolone antibiotic, can increase the survival of motor neuron (SMN) protein levels in human cells and an animal model of spinal muscular atrophy ...

In a randomized controlled trial, researchers compared the standard 6-month tuberculosis treatment to a 4-month rifapentine-moxifloxacin treatment. The study determined the rifapentine-moxifloxacin ...

In one 4-month regimen, rifampin was replaced with rifapentine; in the other, rifampin was replaced with rifapentine and ethambutol with moxifloxacin. The primary efficacy outcome was survival ...